Located in Franklin, Mass, PLC has quickly earned a stellar reputation as a medical technology company specializing in innovative technologies for the cardiac and vascular markets. Today, PLC took a major step towards prominence with the announcement they have added Susan Papalia, RN, BSN, as their Vice President of Clinical Affairs.
In her new role, Papalia will be responsible for overseeing and leading the U.S. clinical study of PLC’s RenalGuard. In only a short period of time, RenalGuard has obtained the CE Mark in the European Union. PLC now plans to commence the pivotal trial in the U.S. to seek approval for sales and marketing from the U.S. Food and Drug Administration (FDA).
Leading the team at PLC Medical Systems is Mark R. Tauscher whom serves as the President and Chief Executive Officer. Commenting on the impact of having Susan Papalia undertake this new role, Tauscher was quoted as saying, “Susan brings to PLC more than 20 years of experience in clinical research and regulatory approvals related to the launch of new medical devices in the U.S. and international markets. With her expertise and our innovative technology, we are looking forward to the first subject enrollments in the U.S. pivotal trial for RenalGuard. We are confident that the results will confirm the effectiveness of RenalGuard and the associated RenalGuard Therapy in reducing the incidence of Contrast-Induced Nephropathy (CIN) in at-risk patients, as already demonstrated in the results from the investigator-sponsored REMEDIAL II and MYTHOS clinical trials in Italy.”
Currently, PLC Medical Services is trading in the $0.15 range. With the addition of Papalia and the overall market expansion of the company, PLC Medical Services is a company that savvy investors will consider placing into their portfolio.
To learn more about the company as a whole, visit the corporate website at: www.plcmed.com